Screening for Previous Virus Infection Could Unlock Work Force
(Bloomberg) -- Tests that could reveal whether people have already withstood Covid-19 and gained immunity will soon be widely available in the U.S., in what could be a key step in getting workers back to their jobs and restarting the economy.
New blood tests from Henry Schein Inc. and Becton Dickinson Co. look for antibodies produced in the middle to late stages of infection with Covid-19, the respiratory illness caused by the new coronavirus. Determining whether people have been infected could allow them to return to work without fear of passing along the disease or contracting it.
The test from Melville, New York-based Henry Schein produces results within about 15 minutes using only a blood sample drawn from a pinprick, according to a news release last week. The test from Becton Dickinson and BioMedomics produces similarly fast results and should be available within two weeks, Troy Hopps, a top executive in the company's point-of-care unit, said in a Tuesday interview.
It's unknown whether having had a Covid-19 infection will protect someone from contracting the disease again. However, exposure to a pathogen is generally thought to confer at least a degree of immunity. Covid-19 sufferers will likely have immunity for some time, though experts aren't sure exactly how long.
As such, antibody testing could make it easier to determine whether workers, especially health-care professionals, can return. It could also help public-health officials plot strategy for a second wave of infections.
The tests, which don't require special laboratory equipment and may even not require a medical professional, will alleviate Covid-19 testing shortfalls in the U.S., said Hopps, the executive from Franklin Lakes, New Jersey-based Becton Dickinson.
“They're just not going to be able to fulfill the demand,” he said.
Bloomberg Intelligence analyst Jonathan Palmer said antibody testing is a “meaningful step forward.” More diagnostics-makers will likely make similar announcements over the coming weeks, he said, while cautioning that scaling up production will take time.
Closely held BioMedomics, based in North Carolina, has been shipping its Covid-19 antibody tests all over the globe, with hundreds of thousands sold in China alone, Chief Operating Officer Brad Heidinger said in a previous interview.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.